Upcoming events – Avadel takes on Jazz and Axovant awaits early results
Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.
Sarepta makes history with Roche deal
A bidding war has netted Sarepta the largest-ever licensing deal for a cell or gene therapy. Can Roche make it work?
Plenty of choice remains for buyers of gene therapy
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Gene therapy clinical holds take centre stage
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
Astellas spends $3bn on a bold move into gene therapy
The Japanese group has seen potential in Audentes' manufacturing capabilities as well as its pipeline.
Upcoming events – Biolinerx takes on pancreatic cancer and first data for Homology
Biolinerx’s BL-8040 needs to show improved responses in pancreatic cancer while investors will get a first look at Homology's HMI-102, a gene therapy for…
Gene therapy’s duration is less than Krystal clear
At 90 days data from Krystal Biotech’s epidermolysis bullosa trial looked good. At 120 days there has been some backsliding.
Strong Zolgensma start bodes ill for Biogen
Zolgensma’s impressive early sales figures spur hopes that gene therapy could finally be coming of age.
Why Novo Nordisk should buy Uniqure
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
